Your browser doesn't support javascript.
loading
Post-recurrence survival in patients with cervical cancer.
Cibula, David; Dostálek, Lukás; Jarkovsky, Jiri; Mom, Constantijne H; Lopez, Aldo; Falconer, Henrik; Scambia, Giovanni; Ayhan, Ali; Kim, Sarah H; Isla Ortiz, David; Klat, Jaroslav; Obermair, Andreas; Di Martino, Giampaolo; Pareja, Rene; Manchanda, Ranjit; Kostun, Jan; Dos Reis, Ricardo; Meydanli, Mehmet Mutlu; Odetto, Diego; Laky, Rene; Zapardiel, Ignacio; Weinberger, Vit; Benesová, Klára; Borcinová, Martina; Cardenas, Fernando; Wallin, Emelie; Pedone Anchora, Luigi; Akilli, Huseyin; Abu-Rustum, Nadeem R; Barquet-Muñoz, Salim Abraham; Javurková, Veronika; Fischerová, Daniela; van Lonkhuijzen, Luc R C W.
Afiliação
  • Cibula D; Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), Prague, Czech Republic. Electronic address: dc@davidcibula.cz.
  • Dostálek L; Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), Prague, Czech Republic.
  • Jarkovsky J; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Mom CH; Amsterdam University Medical Centers, Center for Gynaecologic Oncology Amsterdam, Amsterdam, the Netherlands.
  • Lopez A; Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru.
  • Falconer H; Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Scambia G; Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy.
  • Ayhan A; Baskent University, School of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Ankara, Turkey.
  • Kim SH; Memorial Sloan Kettering Cancer Center, USA.
  • Isla Ortiz D; Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico.
  • Klat J; Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic.
  • Obermair A; Queensland Centre for Gynaecological Cancer, The University of Queensland, Australia.
  • Di Martino G; University of Milano-Bicocca, Department of Obstetrics and Gynecology, Gynaecologic Oncology Surgical Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy.
  • Pareja R; Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Manchanda R; Wolfson Institute of Preventive Medicine, Barts Cancer Centre, Queen Mary University of London, & Barts Health NHS Trust, London, UK.
  • Kostun J; Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
  • Dos Reis R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Meydanli MM; Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Odetto D; Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina.
  • Laky R; Gynecology, Medical University of Graz, Graz, Austria.
  • Zapardiel I; Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain.
  • Weinberger V; University Hospital Brno, Medical Faculty of Masaryk University, Czech Republic.
  • Benesová K; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Borcinová M; Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), Prague, Czech Republic.
  • Cardenas F; Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru.
  • Wallin E; Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Pedone Anchora L; Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy.
  • Akilli H; Baskent University, School of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Ankara, Turkey.
  • Abu-Rustum NR; Memorial Sloan Kettering Cancer Center, USA.
  • Barquet-Muñoz SA; Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico.
  • Javurková V; Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic.
  • Fischerová D; Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), Prague, Czech Republic.
  • van Lonkhuijzen LRCW; Amsterdam University Medical Centers, Center for Gynaecologic Oncology Amsterdam, Amsterdam, the Netherlands.
Gynecol Oncol ; 164(2): 362-369, 2022 02.
Article em En | MEDLINE | ID: mdl-34955236
ABSTRACT

BACKGROUND:

Up to 26% of patients with early-stage cervical cancer experience relapse after primary surgery. However, little is known about which factors influence prognosis following disease recurrence. Therefore, our aims were to determine post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors for PR-DSS.

METHODS:

Data from 528 patients with early-stage cervical cancer who relapsed after primary surgery performed between 2007 and 2016 were obtained from the SCANN study (Surveillance in Cervical CANcer). Factors related to the primary disease and recurrence were combined in a multivariable Cox proportional hazards model to predict PR-DSS.

RESULTS:

The 5-year PR-DSS was 39.1% (95% confidence interval [CI] 22.7%-44.5%), median disease-free interval between primary surgery and recurrence (DFI1) was 1.5 years, and median survival after recurrence was 2.5 years. Six significant variables were identified in the multivariable analysis and were used to construct the prognostic model. Two were related to primary treatment (largest tumour size and lymphovascular space invasion) and four to recurrence (DFI1, age at recurrence, presence of symptoms, and recurrence type). The C-statistic after 10-fold cross-validation of prognostic model reached 0.701 (95% CI 0.675-0.727). Three risk-groups with significantly differing prognoses were identified, with 5-year PR-DSS rates of 81.8%, 44.6%, and 12.7%.

CONCLUSIONS:

We developed the robust model of PR-DSS to stratify patients with relapsed cervical cancer according to risk profiles using six routinely recorded prognostic markers. The model can be utilised in clinical practice to aid decision-making on the strategy of recurrence management, and to better inform the patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Neoplasias do Colo do Útero / Carcinoma Neuroendócrino / Carcinoma Adenoescamoso / Recidiva Local de Neoplasia Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Neoplasias do Colo do Útero / Carcinoma Neuroendócrino / Carcinoma Adenoescamoso / Recidiva Local de Neoplasia Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article